“Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial” (2023) SKIN The Journal of Cutaneous Medicine, 7(4), p. s218. doi:10.25251/skin.7.supp.218.